Patrick Michael Grierson, MD, PhD ...

Dr. Patrick Grierson

Claim this profile

Washington University School of Medicine

Studies Pancreatic Cancer
Studies Colorectal Cancer
20 reported clinical trials
46 drugs studied

Area of expertise

1Pancreatic Cancer
Patrick Grierson has run 8 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive
2Colorectal Cancer
Patrick Grierson has run 8 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
Mismatch Repair Deficiency positive

Affiliated Hospitals

Image of trial facility.
Washington University School Of Medicine
Image of trial facility.
Siteman Cancer Center At West County Hospital

Clinical Trials Patrick Grierson is currently running

Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Image of trial facility.

NT-112

for Solid Tumors

This trial tests NT-112, a personalized immune cell treatment, in patients with advanced cancers that have a specific genetic mutation. The treatment boosts the patient's immune cells to target and kill cancer cells. This highly personalized cancer therapy involves giving the patient immune cells that directly attack cancer.
Recruiting1 award Phase 13 criteria

More about Patrick Grierson

Clinical Trial Related1 year of experience running clinical trials · Led 20 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Patrick Grierson has experience with
  • Leucovorin
  • Fluorouracil
  • Nivolumab
  • Oxaliplatin
  • Pembrolizumab
  • Trastuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Patrick Grierson specialize in?
Is Patrick Grierson currently recruiting for clinical trials?
Are there any treatments that Patrick Grierson has studied deeply?
What is the best way to schedule an appointment with Patrick Grierson?
What is the office address of Patrick Grierson?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security